Survodutide – Dual GLP-1 & Glucagon Peptide for Laboratory Research

Survodutide (BI 456906) is an innovative peptide currently undergoing late-stage clinical trials. It combines GLP-1 and glucagon receptor agonism , allowing researchers to study the combined effects of appetite regulation and energy metabolism in laboratory models. Myotrope supplies high-purity Survodutide, including a COA test report, specifically for preclinical research on weight loss, fat burning, regenerative tissue repair, and metabolic health.

How does Survodutide work?

Survodutide activates two hormonal pathways simultaneously, which is unique to this peptide:

• GLP-1 receptor agonism: Reduces caloric intake, promotes satiety and stabilizes glucose
• Glucagon receptor agonism: Stimulates energy expenditure and fat metabolism in the liver
• Additive effect: Researchers can better measure effects on weight loss, energy metabolism and fat mass
• Being studied in combination with other peptides for regenerative tissue repair and metabolic synergy

Benefits of Survodutide

• Supports research into weight loss and fat burning
• Promotes energy expenditure and metabolic balance in models
• Used in studies of obesity, diabetes and fatty liver disease (MASH)
• Helps researchers measure caloric intake and fat mass

Legal disclaimer

Survodutide is intended for laboratory research only . Not for human consumption or therapeutic use. All described effects are based on preclinical studies and clinical trials.

Want to know more?

Read our comprehensive blog on dual agonist peptides or discover other peptides for research through Myotrope.